Search research articles
Contact Us
Filters
Showing results (21-30 of 39) with videos related to
Page
of 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2003
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?
Giovanna Masci, Massimo Magagnoli, Paolo Andrea Zucali, et al.
American Journal of Hematology
|
July 25, 2003
Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution
Massimo Magagnoli, Luca Castagna, Monica Balzarotti, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
April 20, 2006
Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications
Giovanna Masci, Massimo Magagnoli, Vittorio Pedicini, et al.
American Journal of Hematology
|
October 5, 2006
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study
Luca Castagna, Massimo Magagnoli, Monica Balzarotti, et al.
European Journal of Haematology
|
February 23, 2007
CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients
Elisabetta Todisco, Luca Castagna, Barbara Sarina, et al.
Haematologica
|
January 19, 2007
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma
Armando Santoro, Massimo Magagnoli, Michele Spina, et al.
Investigational New Drugs
|
February 1, 2021
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma
Monica Balzarotti, Massimo Magagnoli, Miguel Ángel Canales, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 17, 2009
Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma
Luca Castagna, Barbara Sarina, Elisabetta Todisco, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 26, 2019
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study
Carmelo Carlo-Stella, Richard Delarue, Lydia Scarfo, et al.
British Journal of Haematology
|
April 7, 2009
Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy
Luca Castagna, Stefania Bramanti, Monica Balzarotti, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 39) with videos related to
Sort By:
Page
of 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2003
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy?
Giovanna Masci, Massimo Magagnoli, Paolo Andrea Zucali, et al.
American Journal of Hematology
|
July 25, 2003
Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution
Massimo Magagnoli, Luca Castagna, Monica Balzarotti, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
April 20, 2006
Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications
Giovanna Masci, Massimo Magagnoli, Vittorio Pedicini, et al.
American Journal of Hematology
|
October 5, 2006
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study
Luca Castagna, Massimo Magagnoli, Monica Balzarotti, et al.
European Journal of Haematology
|
February 23, 2007
CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients
Elisabetta Todisco, Luca Castagna, Barbara Sarina, et al.
Haematologica
|
January 19, 2007
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma
Armando Santoro, Massimo Magagnoli, Michele Spina, et al.
Investigational New Drugs
|
February 1, 2021
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma
Monica Balzarotti, Massimo Magagnoli, Miguel Ángel Canales, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 17, 2009
Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma
Luca Castagna, Barbara Sarina, Elisabetta Todisco, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 26, 2019
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study
Carmelo Carlo-Stella, Richard Delarue, Lydia Scarfo, et al.
British Journal of Haematology
|
April 7, 2009
Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy
Luca Castagna, Stefania Bramanti, Monica Balzarotti, et al.
Page
of 4